PRE
Prenetics Global Ltd.
NASDAQ · Healthcare · Medical - Diagnostics & Research · HK
$19.02
+2.70%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$18.75
From 52W high−27.54%
Volume167862.00
Market cap$322.16M
P/E (TTM)—
P/S (TTM)2.3x
Div yield—
Key dataOct 19, 2026
Open
$18.75
From 52W high
−27.54%
Volume
167862.00
Market cap
$322.16M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.4x
P/E (TTM)
—
RSI (14)
35.4
MomentumView details →
1D Return
+2.70%
YTD Return
+19.85%
SummaryUpdated Jun 1, 2026
Prenetics Global Limited (NASDAQ:PRE) is a Hong Kong-based diagnostics and genetic testing company founded in 2014 that went public in July 2021. The company operates as an investment holding company with subsidiaries focused on developing and commercializing consumer genetic testing products, rapid diagnostic tests, and health monitoring systems. Prenetics has positioned itself in the growing personalized healthcare market, offering direct-to-consumer genetic testing alongside point-of-care diagnostic solutions.
Similar companies
Latest newsMore news →
Prenetics Global Limited CEO Danny Yeung and CFO Brian Rosin purchased $1.0 million of the company's ordinary shares in the open market between August 20 and August 25, 2026, following the release of second quarter 2026 financial results.54d agoPrenetics Global Limited held its Q2 2026 earnings call on August 22, 2026.59d agoPrenetics announced it will report its Q2 2026 financial results on August 18, 2026, and will live-stream the earnings event on Stocktwits.73d ago